Effect of Pravastatin As an Adjunctive Therapeutic for Mitral Insufficiency with Hyperlipidemia in a Dog

Overview

Journal Case Rep Vet Med

Publisher Wiley

Specialty Veterinary Medicine

Date 2021 Sep 17

PMID 34532150

Authors

Yu Sahashi

Miwako Sahashi

Yoshiaki Hikasa

Affiliations

Soon will be listed here.

Abstract

Pravastatin (PS) has been found to increase left ventricle (LV) expansion capacity and decrease LV constriction and left atrial pressure in healthy dogs. To date, there are no available reports on the effects of PS in dogs with hypercholesterolemia with chronic heart failure (CHF). This case report demonstrates a successful long-term treatment plan using PS in a dog suffering from mitral insufficiency with hyperlipidemia. A 12-year-old, castrated male Chihuahua dog had mitral insufficiency with hyperlipidemia. The dog presented with symptoms of chronic coughing. PS was orally administered (1 mg/kg, SID) in addition to general treatment for mitral insufficiency. The follow-up period was 375 days. PS administration decreased the heart rate (HR), vertebral heart size (VHS), and N-terminal probrain natriuretic peptide (NT-proBNP) concentration of the dog. In addition, PS administration also improved chronic cardiac failure induced by mitral insufficiency and hyperlipidemia. This report suggests that PS can be useful as an adjunctive therapeutic for dogs with hypercholesterolemia with mitral insufficiency.

References

Nickenig G, Baumer A, Temur Y, Kebben D, Jockenhovel F, Bohm M . Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999; 100(21):2131-4. DOI: 10.1161/01.cir.100.21.2131. View

Giaid A, Yanagisawa M, Langleben D, Michel R, Levy R, Shennib H . Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993; 328(24):1732-9. DOI: 10.1056/NEJM199306173282402. View

Pliquett R, Cornish K, Peuler J, Zucker I . Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation. 2003; 107(19):2493-8. DOI: 10.1161/01.CIR.0000065606.63163.B9. View

Rikitake Y, Liao J . Rho GTPases, statins, and nitric oxide. Circ Res. 2005; 97(12):1232-5. PMC: 2633589. DOI: 10.1161/01.RES.0000196564.18314.23. View

Moonarmart W, Boswood A, Luis Fuentes V, Brodbelt D, Souttar K, Elliott J . N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract. 2010; 51(2):84-96. DOI: 10.1111/j.1748-5827.2009.00889.x. View

Verma S, Rao V, Weisel R, Li S, Fedak P, Miriuka S . Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells. J Surg Res. 2004; 119(1):66-71. DOI: 10.1016/j.jss.2003.10.011. View

Jain M, Ridker P . Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005; 4(12):977-87. DOI: 10.1038/nrd1901. View

Horiuchi M, Cui T, Li Z, Li J, Nakagami H, Iwai M . Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation. 2003; 107(1):106-12. DOI: 10.1161/01.cir.0000043244.13596.20. View

Arita S, Arita N, Hikasa Y . Effect of pravastatin on echocardiographic circulation parameters in dogs. J Vet Med Sci. 2013; 76(4):481-9. PMC: 4064130. DOI: 10.1292/jvms.13-0505. View

10.

Ramasubbu K, Estep J, White D, Deswal A, Mann D . Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol. 2008; 51(4):415-26. DOI: 10.1016/j.jacc.2007.10.009. View

11.

Giaid A, Saleh D . Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995; 333(4):214-21. DOI: 10.1056/NEJM199507273330403. View

12.

Borgarelli M, Savarino P, Crosara S, Santilli R, Chiavegato D, Poggi M . Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med. 2008; 22(1):120-8. DOI: 10.1111/j.1939-1676.2007.0008.x. View

13.

van der Harst P, Wagenaar L, Buikema H, Voors A, Thijs Plokker H, Morshuis W . Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease. Am J Cardiol. 2005; 96(10):1361-4. DOI: 10.1016/j.amjcard.2005.07.052. View

14.

Strehlow K, Wassmann S, Bohm M, Nickenig G . Angiotensin AT1 receptor over-expression in hypercholesterolaemia. Ann Med. 2000; 32(6):386-9. DOI: 10.3109/07853890008995944. View